PYRIDO (2, 3-D) PYRIMIDINONE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS
Spoj Formule (I) ili njegova sol, naznačen time što: R1 je H ili (C1 do C8) alkil, izborno supstituiran s najmanje jednom skupinom R5;A je 3- do 10-eročlana cikloalkilna skupina; R2 je (C1 do C8) alkil, supstituiran s najmanje jednom skupinom R6, (C3 do C10) cikloalkil, (C2 do C8) cikloheteroalkil,...
Saved in:
Main Authors | , , , , , , , , , , |
---|---|
Format | Patent |
Language | Croatian English |
Published |
30.09.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Spoj Formule (I) ili njegova sol, naznačen time što: R1 je H ili (C1 do C8) alkil, izborno supstituiran s najmanje jednom skupinom R5;A je 3- do 10-eročlana cikloalkilna skupina; R2 je (C1 do C8) alkil, supstituiran s najmanje jednom skupinom R6, (C3 do C10) cikloalkil, (C2 do C8) cikloheteroalkil, (C8 do C14) aril, (C2 do C9) heteroaril, -NR7aR7b ili -N=CR8aR8b, gdje je svaki od navedenih (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C8 do C14) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R9;R3 je (C1 do C6) alkil, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C2 do C8) alkenil, (C2 do C8) alkinil, halogen, cijano, -(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), COR12, (C8 do C14) aril ili (C2 do C9) heteroaril, gdje su navedeni (C1 do C6) alkil, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C2 do C8) alkenil, (C2 do C8) alkinil, (C8 do C14) aril i (C2 do C9) heteroaril izborno supstituirani s najmanje jednom skupinom R9;svaki R4 je neovisno -OH, halogen, CF3, -NR11aR11b, (C1 do C8) alkil, (C1 do C6) alkenil, (C1 do C8) alkinil, (C1 do C6) alkoksi, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C8 do C14) aril, (C2 do C9) heteroaril, -C(O)R12-C(O)NR11aR11b, -S(O)mR12, -S(O)mNR11aR11b, -NR11aS(O)mR12-(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), -OC(O)R12, -NR11aC(O)R12 ili -NR11aC(O)N(R11aR11b), gdje je svaki od navedenih (C1 do C6) alkila, (C1 do C6) alkenila, (C1 do C6) alkinila, (C1 do C6) alkoksi, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C12) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R13;svaki R5 je neovisno -OH, halogen, CF3, -NR11aR11b, (C1 do C6) alkil, (C1 do C6) alkoksi, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C6 do C14) aril, (C2 do C9) heteroaril, -S(O)mR12, -S(O)mR11aR11b, -C(O)R12 ili -C(O)NR11aR11b, gdje je svaki od navedenih (C1 do C6) alkila, (C1 do C6) alkoksi, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C14) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R9;svaki R6 je neovisno -OH, (C1 do C6) alkinil, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C8 do C14) aril, (C2 do C8) heteroaril, -C(O)R12 -C(O)NR11aR11b, -S(O)mR12, -S(O)mNR11aR11b, -NR11aS(O)mR12-(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), -OC(O)R12, -NR11aC(O)R12 ili -NR11aC(O)N(R11aR11b), gdje je svaki od navedenih (C1 do C6) alkinila, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C12) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R13;svaki od R7a i R7b je neovisno H, (C1 do C8) alkil, (C2 do C6)alkenil, (C2 do C6)alkinil, (C3 do C10) cikloalkil ili (C6 do C10)aril, gdje je svaki od navedenih (C1 do C6) alkila, (C2 do C6)alkenila, (C2 do C6)alkinila, (C3 do C10) cikloalkila, te (C6 do C10)arila izborno supstituiran s najmanje jednom skupinom R9; ili se R7a i R7b može uzeti zajedno s atomom dušika kako bi tvorili
The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-Kalpha). |
---|---|
AbstractList | Spoj Formule (I) ili njegova sol, naznačen time što: R1 je H ili (C1 do C8) alkil, izborno supstituiran s najmanje jednom skupinom R5;A je 3- do 10-eročlana cikloalkilna skupina; R2 je (C1 do C8) alkil, supstituiran s najmanje jednom skupinom R6, (C3 do C10) cikloalkil, (C2 do C8) cikloheteroalkil, (C8 do C14) aril, (C2 do C9) heteroaril, -NR7aR7b ili -N=CR8aR8b, gdje je svaki od navedenih (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C8 do C14) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R9;R3 je (C1 do C6) alkil, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C2 do C8) alkenil, (C2 do C8) alkinil, halogen, cijano, -(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), COR12, (C8 do C14) aril ili (C2 do C9) heteroaril, gdje su navedeni (C1 do C6) alkil, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C2 do C8) alkenil, (C2 do C8) alkinil, (C8 do C14) aril i (C2 do C9) heteroaril izborno supstituirani s najmanje jednom skupinom R9;svaki R4 je neovisno -OH, halogen, CF3, -NR11aR11b, (C1 do C8) alkil, (C1 do C6) alkenil, (C1 do C8) alkinil, (C1 do C6) alkoksi, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C8 do C14) aril, (C2 do C9) heteroaril, -C(O)R12-C(O)NR11aR11b, -S(O)mR12, -S(O)mNR11aR11b, -NR11aS(O)mR12-(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), -OC(O)R12, -NR11aC(O)R12 ili -NR11aC(O)N(R11aR11b), gdje je svaki od navedenih (C1 do C6) alkila, (C1 do C6) alkenila, (C1 do C6) alkinila, (C1 do C6) alkoksi, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C12) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R13;svaki R5 je neovisno -OH, halogen, CF3, -NR11aR11b, (C1 do C6) alkil, (C1 do C6) alkoksi, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C6 do C14) aril, (C2 do C9) heteroaril, -S(O)mR12, -S(O)mR11aR11b, -C(O)R12 ili -C(O)NR11aR11b, gdje je svaki od navedenih (C1 do C6) alkila, (C1 do C6) alkoksi, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C14) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R9;svaki R6 je neovisno -OH, (C1 do C6) alkinil, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C8 do C14) aril, (C2 do C8) heteroaril, -C(O)R12 -C(O)NR11aR11b, -S(O)mR12, -S(O)mNR11aR11b, -NR11aS(O)mR12-(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), -OC(O)R12, -NR11aC(O)R12 ili -NR11aC(O)N(R11aR11b), gdje je svaki od navedenih (C1 do C6) alkinila, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C12) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R13;svaki od R7a i R7b je neovisno H, (C1 do C8) alkil, (C2 do C6)alkenil, (C2 do C6)alkinil, (C3 do C10) cikloalkil ili (C6 do C10)aril, gdje je svaki od navedenih (C1 do C6) alkila, (C2 do C6)alkenila, (C2 do C6)alkinila, (C3 do C10) cikloalkila, te (C6 do C10)arila izborno supstituiran s najmanje jednom skupinom R9; ili se R7a i R7b može uzeti zajedno s atomom dušika kako bi tvorili
The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-Kalpha). |
Author | MITCHELL DAVID NAMBU KLAUS RUPRECHT DRESS HENGMIAO CHENG JACQUI ELIZABET HOFFMAN PHUONG THI QUY LE ROBERT STEVEN KANIA DILIP BHUMRALKAR MARY CATHERINE JOHNSON MASON ALAN PAIRISH MICHAEL BRUNO PLEWE KHANH TUAN TRAN |
Author_xml | – fullname: DILIP BHUMRALKAR – fullname: ROBERT STEVEN KANIA – fullname: MITCHELL DAVID NAMBU – fullname: MICHAEL BRUNO PLEWE – fullname: MARY CATHERINE JOHNSON – fullname: MASON ALAN PAIRISH – fullname: PHUONG THI QUY LE – fullname: KHANH TUAN TRAN – fullname: KLAUS RUPRECHT DRESS – fullname: JACQUI ELIZABET HOFFMAN – fullname: HENGMIAO CHENG |
BookMark | eNrjYmDJy89L5WRwC4gM8nTxV9Aw0lEw1nXRVADxfT1dPP38_VwVnP19A_xD_VyCFRz9XBRCPFw9gxRCg10VHIMVAjyNFTz9PDydPEP8g4J5GFjTEnOKU3mhNDeDsptriLOHbmpBfnxqcUFicmpeakm8R1CAkYGhoYGZkWFIiKExcaoAHDIumw |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3 |
ExternalDocumentID | HRP20110621TT1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_HRP20110621TT13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 13:59:36 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Croatian English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_HRP20110621TT13 |
Notes | Application Number: HR2011P000621T |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110930&DB=EPODOC&CC=HR&NR=P20110621T1 |
ParticipantIDs | epo_espacenet_HRP20110621TT1 |
PublicationCentury | 2000 |
PublicationDate | 20110930 |
PublicationDateYYYYMMDD | 2011-09-30 |
PublicationDate_xml | – month: 09 year: 2011 text: 20110930 day: 30 |
PublicationDecade | 2010 |
PublicationYear | 2011 |
RelatedCompanies | PFIZER PRODUCTS INC |
RelatedCompanies_xml | – name: PFIZER PRODUCTS INC |
Score | 2.8256803 |
Snippet | Spoj Formule (I) ili njegova sol, naznačen time što: R1 je H ili (C1 do C8) alkil, izborno supstituiran s najmanje jednom skupinom R5;A je 3- do 10-eročlana... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | PYRIDO (2, 3-D) PYRIMIDINONE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110930&DB=EPODOC&locale=&CC=HR&NR=P20110621T1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dS8Mw8BhT1DeditMpAaUoWFy7ftCHImvT0ghNStvJfBpr14II3XAV_75pXJ1Pe0tycFwOLveR-wC4My19UQ6HC1nXi1zWFDOXraK0ZM1smpepWmmIvgUhNYKJ9jLVpx34aGthRJ_Qb9EckUtUzuW9Fu_1ahvEwiK3cv2UvfOj5bOf2lhatOE-7qAPJezYXsQwcyXXtYNYorEdCaChKil3lfa4HW024uC9Ok1Zyuq_TvGPYT_i6Kr6BDpF1YNDtx291oODcPPjzZcb4Vufgh-9xQQzdK8-opGMH1CzDwkmlFEPuSyM2ITiBI0pRmngkRhNEg-NExSRESI0IA5JWZycwa3vpW4gc4Jmf9efBfGW-FQZnUO3WlbFBSAr15XcUOdzrpS1rJlxzrlbzEtuVZhqqWd9GOzCdLkbfAVHv_HTJjdiAN3686u45gq4zm4E434Aw-6Bug |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dS8Mw8BhTnG86FT-mBpSiYHHt-kEfimxNS6JrWtpO5tNYuxZE6Iar-PdN4-Z82luSg-NycLmP3AfArWnps6Lbncm6nmeyppiZbOWFJWtm3bxM1QpD9C3wmUFG2vNYHzfgY10LI_qEfovmiFyiMi7vlXivF5sgFha5lcvH9J0fzZ-8xMbSbB3u4w56V8ID2w0DHDiS49gkklhkhwJoqErCXaUdbmObtTi4r4O6LGXxX6d4B7AbcnRldQiNvGxDy1mPXmvDnr_68ebLlfAtj8AL3yKKA3SnPqCejO9RvfcppixgLnICPwxGDMeozzBKiEsjNIpd1I9RSHuIMkIHNAmi-BhuPDdxiMwJmvxdf0KiDfGJ0juBZjkv81NAVqYrmaFOp1wpa2k945xzN58W3Kow1UJPz6CzDdP5dvA1tEjiDydDyl4uYP83llrnSXSgWX1-5ZdcGVfplWDiDwWehK0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PYRIDO+%282%2C+3-D%29+PYRIMIDINONE+COMPOUNDS+AND+THEIR+USE+AS+PI3+INHIBITORS&rft.inventor=DILIP+BHUMRALKAR&rft.inventor=ROBERT+STEVEN+KANIA&rft.inventor=MITCHELL+DAVID+NAMBU&rft.inventor=MICHAEL+BRUNO+PLEWE&rft.inventor=MARY+CATHERINE+JOHNSON&rft.inventor=MASON+ALAN+PAIRISH&rft.inventor=PHUONG+THI+QUY+LE&rft.inventor=KHANH+TUAN+TRAN&rft.inventor=KLAUS+RUPRECHT+DRESS&rft.inventor=JACQUI+ELIZABET+HOFFMAN&rft.inventor=HENGMIAO+CHENG&rft.date=2011-09-30&rft.externalDBID=T1&rft.externalDocID=HRP20110621TT1 |